Skip to main content
Home
    • en
    • fr
  • Search form

Main menu

  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux

  • Responsibility
    • Our commitments
    • Responsibility to society
    • Responsibility to our workforce
    • Responsibility to the environment
    • Ethics & Compliance
    • Sustainable and socially inclusive purchasing
    • Global Compact
    • Internal Audit & Risks
    • FONDATION MÉRIEUX
    • OUR EMPLOYEE'S SUCCESS
  • Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity & data privacy
    • Technical Library
    • CLINICAL SOLUTIONS
    • INDUSTRY SOLUTIONS
  • Expertise
    • The importance of diagnostics
      • Clinical diagnostics
      • Industrial Microbiological Control
    • Clinical applications
      • Infectious diseases
      • COVID-19
      • Antimicrobial resistance and Healthcare-associated infections
      • Cardiovascular Emergencies
      • Personalized medicine
    • Industrial applications
      • Agri-food sector
      • Biopharma & cosmetics sectors
    • Our technologies, systems and services
      • Microbiology
      • Molecular Biology
      • Immunoassays
      • Laboratory efficiency
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
      • Webinars
      • Educational Materials
      • External Resources
    • Sepsis / Bloodstream Infections
      • Webinars
      • Educational Tutorials
      • Educational Materials
      • External Resources
    • COVID-19
      • Webinars
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
    • UNIVERSAL REGISTRATION DOCUMENT
    • CORPORATE SOCIAL RESPONSIBILITY
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
    • bioMérieux announces the CE marking of its molecular biology ARGENE® test for the simultaneous detection of SARS-CoV-2, influenza viruses A and B, and RSV and hMPV viruses
    • PRESS CONTACTS
     
  • Careers
    • Joining bioMérieux
      • Corporate culture
      • Public health mission
      • International presence
      • Professional development
      • Diversity and inclusion
      • Well-being at work
      • Compensation and benefits
    • Job Profiles
      • R&D
      • Manufacturing
      • Supply Chain
      • Information Systems
      • Quality
      • Business
      • Support Functions
      • Medical Affairs
      • HSE
      • Clinical Affairs and Regulatory Affairs
  • Contact us
Home
  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux
  • Responsibility
    • Our commitments
    • Responsibility to society
    • Responsibility to our workforce
    • Responsibility to the environment
    • Ethics & Compliance
    • Sustainable and socially inclusive purchasing
    • Global Compact
    • Internal Audit & Risks
  • Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity & data privacy
    • Technical Library
  • Expertise
    • The importance of diagnostics
    • Clinical applications
    • Industrial applications
    • Our technologies, systems and services
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
    • Sepsis / Bloodstream Infections
    • COVID-19
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
  • Careers
    • Joining bioMérieux
    • Job Profiles
  • Contact us
    • Investor Relations
    • Press Contacts
    • en
    • fr
  • Search form

You are here

Printer-friendly version
  • Home
  • Investors
  • Publications
  • Universal Registration Documents
Investors
  • The bioMérieux Share
    • Stock Market Information
    • Historic Chart
    • Analysts Coverage
    • Analysts Consensus
  • Publications
    • Calendar
    • Press Releases
    • Presentations
    • Annual Reports
    • Universal Registration Documents
  • Regulated Information
  • Governance
    • Regulated Agreements
    • Status
    • Board Charter
  • Shareholder area
    • General Shareholders' Meeting
    • Participating In The General Shareholder's Meeting
    • Dividends
    • Crossing the Thresholds

Universal Registration Documents

Universal Registration Document 2019

April 10, 2020

Registration Document including Annual Financial Report 2018

March 15, 2019

Registration Document including Annual Financial Report 2017

March 15, 2018

Registration Document including Annual Financial Report 2016

March 31, 2017

Registration Document 2015

March 17, 2016

Registration Document 2015

March 17, 2016

Registration Document 2014

June 25, 2015

Registration Document 2012

May 21, 2013

Registration Document 2011

April 27, 2012

Registration Document 2010

September 01, 2010
  • ‹ previous
  • 1
  • 2
  • next ›

 

Contact Us

Contact Us

 

Pioneering diagnostics
  • Legal Notice
  • Privacy
  • Cookie Policy
  • Contact
  • Copyright 2020 bioMérieux SA
  • biomerieux.com
  • bioMérieux Worldwide >
    Discover all our locations
    Asia
    • China (Website)
    • Korea
    Europe, Middle East, Africa
    • Algeria
    • Belgium
    • Greece
    • Ivory Coast
    • Netherlands
    • Serbia
    • Turkey (Website)
    • United Arab Emirates
    North America
    Oceania
    • Australia (Website)
    • New Zealand (Website)
    South America
    • Argentina (Website)
    • Brazil (Website)
    • Colombia (Website)
    • Mexico (Website)
  • Our Specific Websites >
  • Our communities >